North America Glaucoma Procedures Market Outlook: Data and Trends Through 2030
January 29, 2024 12:08 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "North America Glaucoma Procedures Count by Segments and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report...
Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling
January 29, 2024 12:05 ET
|
Doheny Eye Institute
PASADENA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, is pleased to announce the publication of important new findings...
LUMIBIRD: 2023 REVENUES AT €203.6M
January 29, 2024 11:46 ET
|
Lumibird SA
Lannion, the 29/01/2024 - 17h45 LUMIBIRD: 2023 REVENUES AT €203.6M Organic1 revenues (€200.8m) are in line with the latest forecasts (+7.5% on a like-for-like basis and at constant exchange...
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
January 29, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company...
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
January 29, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and...
LUMIBIRD: FINANCIAL COMMUNICATIONS AGENDA
January 26, 2024 10:10 ET
|
Lumibird SA
Lannion, January 26, 2024 FINANCIAL COMMUNICATIONS AGENDA LUMIBIRD [FR0000038242 – LBIRD], the European leader for laser technologies, publishes its financial communications agenda for 2024....
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
January 26, 2024 07:06 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Biomaterials Market to Touch USD 470 Billion at 14.5% CAGR by 2032, According to Persistence Market Research
January 26, 2024 01:51 ET
|
Persistence Market Research
New York, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The biomaterials industry encompasses the development and utilization of materials that interact with biological systems, with diverse applications in...
Non-Infectious Macular Edema Treatment Market Set to Experience Exponential Growth by 2031 with Prominent Demand for Corticosteroids in North America and Europe
January 25, 2024 06:19 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology,...
Vitrectomy Devices Market Forecast to Surge at Rapid Pace Due to Rising Retinal Disorders and Technological Innovations by 2028
January 25, 2024 05:19 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Vitrectomy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2028" report has been added to ResearchAndMarkets.com's offering. ...